Citadel Advisors’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.5K | Buy |
+21,200
| New | +$25.7K | ﹤0.01% | 12678 |
|
|
2025
Q2 | – | Sell |
-36,600
| Closed | -$39.5K | – | 13921 |
|
|
2025
Q1 | $39.5K | Buy |
36,600
+6,300
| +21% | +$8.85K | ﹤0.01% | 12549 |
|
|
2024
Q4 | $53K | Buy |
30,300
+16,200
| +115% | +$30.2K | ﹤0.01% | 12334 |
|
|
2024
Q3 | $27.2K | Sell |
14,100
-6,600
| -32% | -$12.9K | ﹤0.01% | 12523 |
|
|
2024
Q2 | $36.6K | Buy |
20,700
+20,300
| +5,075% | +$49.6K | ﹤0.01% | 12073 |
|
|
2024
Q1 | $1.08K | Buy |
400
+100
| +33% | +$241 | ﹤0.01% | 14185 |
|
|
2023
Q4 | $663 | Buy |
300
+200
| +200% | +$427 | ﹤0.01% | 13973 |
|
|
2023
Q3 | $290 | Buy |
+100
| New | +$262 | ﹤0.01% | 14095 |
|
|
2023
Q2 | – | Sell |
-25,800
| Closed | -$50.3K | – | 14839 |
|
|
2023
Q1 | $50.3K | Buy |
25,800
+21,000
| +438% | +$41.5K | ﹤0.01% | 12133 |
|
|
2022
Q4 | $5.62K | Buy |
+4,800
| New | +$5.91K | ﹤0.01% | 13983 |
|
|
2022
Q3 | – | Sell |
-17,100
| Closed | -$27K | – | 13159 |
|
|
2022
Q2 | $27K | Sell |
17,100
-3,400
| -17% | -$8.41K | ﹤0.01% | 12276 |
|
|
2022
Q1 | $74K | Sell |
20,500
-22,200
| -52% | -$76.7K | ﹤0.01% | 12535 |
|
|
2021
Q4 | $167K | Buy |
42,700
+9,100
| +27% | +$42.6K | ﹤0.01% | 12128 |
|
|
2021
Q3 | $221K | Sell |
33,600
-8,800
| -21% | -$57.9K | ﹤0.01% | 11771 |
|
|
2021
Q2 | $261K | Sell |
42,400
-36,400
| -46% | -$195K | ﹤0.01% | 11609 |
|
|
2021
Q1 | $356K | Buy |
78,800
+23,200
| +42% | +$127K | ﹤0.01% | 10449 |
|
|
2020
Q4 | $334K | Sell |
55,600
-148,800
| -73% | -$978K | ﹤0.01% | 8878 |
|
|
2020
Q3 | $1.52M | Buy |
204,400
+186,000
| +1,011% | +$1.28M | ﹤0.01% | 5241 |
|
|
2020
Q2 | $74K | Buy |
+18,400
| New | +$64.1K | ﹤0.01% | 9135 |
|
|
2018
Q4 | – | Sell |
-14,300
| Closed | -$107K | – | 9480 |
|
|
2018
Q3 | $107K | Buy |
+14,300
| New | +$102K | ﹤0.01% | 8546 |
|
|
2016
Q1 | – | Sell |
-5,500
| Closed | -$59K | – | 7406 |
|
|
2015
Q4 | $59K | Sell |
5,500
-1,800
| -25% | -$17.7K | ﹤0.01% | 7169 |
|
|
2015
Q3 | $59K | Sell |
7,300
-8,900
| -55% | -$140K | ﹤0.01% | 7458 |
|
|
2015
Q2 | $392K | Buy |
16,200
+7,300
| +82% | +$230K | ﹤0.01% | 5347 |
|
|
2015
Q1 | $375K | Buy |
8,900
+5,300
| +147% | +$210K | ﹤0.01% | 5341 |
|
|
2014
Q4 | $121K | Sell |
3,600
-5,200
| -59% | -$147K | ﹤0.01% | 6484 |
|
|
2014
Q3 | $216K | Buy |
8,800
+800
| +10% | +$22.5K | ﹤0.01% | 5650 |
|
|
2014
Q2 | $235K | Buy |
8,000
+7,600
| +1,900% | +$244K | ﹤0.01% | 5380 |
|
|
2014
Q1 | $18K | Buy |
+400
| New | +$17.6K | ﹤0.01% | 7333 |
|
Other funds holding LAB
CC
MCO
LFCM
VCM
HBWM
Citadel Advisors's LAB Position: Q1 2026 in Review
Citadel Advisors increased its Standard BioTools (LAB) stake by 14% in Q1 2026, buying an estimated $180K and bringing the position to 1,225,310 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #7407.
Citadel Advisors first reported a position in LAB in Q4 2013 and has held it in 40 quarters since. The position peaked at $12.2M in Q1 2019. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.
- Citadel Advisors held 1,225,310 shares of Standard BioTools worth $1.13M as of Q1 2026.
- Citadel Advisors bought 148,949 Standard BioTools shares in Q1 2026, an estimated $180K.
- Standard BioTools made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7407 holding.
- Citadel Advisors first reported a position in Standard BioTools in Q4 2013 and has held it in 40 quarters since.
- Citadel Advisors's Standard BioTools position peaked at $12.2M in Q1 2019.
- 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.